4-((E)-((Z)-2-(cyclohexylimino)-4-methylthiazol-3(2H)-ylimino)methyl)benzene-1,2,3-triol

ID: ALA3265288

Chembl Id: CHEMBL3265288

PubChem CID: 135691163

Max Phase: Preclinical

Molecular Formula: C17H21N3O3S

Molecular Weight: 347.44

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  Cc1cs/c(=N\C2CCCCC2)n1/N=C/c1ccc(O)c(O)c1O

Standard InChI:  InChI=1S/C17H21N3O3S/c1-11-10-24-17(19-13-5-3-2-4-6-13)20(11)18-9-12-7-8-14(21)16(23)15(12)22/h7-10,13,21-23H,2-6H2,1H3/b18-9+,19-17-

Standard InChI Key:  RGGFUBMUOVFZEF-LDRVEFRDSA-N

Alternative Forms

1. Parent:

   

   ALA3265288

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 347.44

Molecular Weight (Monoisotopic): 347.1304

AlogP: 3.09

#Rotatable Bonds: 3

Polar Surface Area: 90.34

Molecular Species: NEUTRAL

HBA: 7

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 8.54

CX Basic pKa: 4.25

CX LogP: 3.83

CX LogD: 3.80

Aromatic Rings: 2

Heavy Atoms: 24

QED Weighted: 0.59

Np Likeness Score: -0.68

References

1. Abulwerdi FA, Liao C, Mady AS, Gavin J, Shen C, Cierpicki T, Stuckey JA, Showalter HD, Nikolovska-Coleska Z..  (2014)  3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation.,  57  (10): [PMID:24749893] [10.1021/jm500010b]

2. Nhu D, Lessene G, Huang DCS, Burns CJ.  (2016)  Small molecules targeting Mcl-1: the search for a silver bullet in cancer therapy,  7  (5): [10.1039/C5MD00582E]

3. Wan Y, Dai N, Tang Z, Fang H..  (2018)  Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.,  146  [PMID:29407973] [10.1016/j.ejmech.2018.01.076]

4. Yang S, Mao Y, Zhang H, Xu Y, An J, Huang Z..  (2019)  The chemical biology of apoptosis: Revisited after 17 years.,  177  [PMID:31129454] [10.1016/j.ejmech.2019.05.019]

5. Negi A, Murphy PV..  (2021)  Development of Mcl-1 inhibitors for cancer therapy.,  210  [PMID:33333396] [10.1016/j.ejmech.2020.113038]

Source

Source(1):

• Scientific Literature